Takeda, Sage Bionetworks Partner to Find Drug Targets for CNS | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –Takeda Pharmaceutical and Sage Bionetworks announced on Thursday a collaboration to identify drug targets for central nervous system diseases.

Under the agreement, Takeda, based in Osaka, Japan, will pay Sage $3.6 million in research funding and fees. Sage will develop a predictive model and identify key regulatory genes and predictive biomarkers in patients with CNS diseases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.